Skip to content
Catalyst

PapersPMID:40918053

Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial.

Nature and science of sleep2025The record ↗

  1. Finding, moderate evidencelowersInsomnia Severity Index (ISI) total score

What moved

1 findingHow to read these marks →
  • “Based on the intention-to-treat GLMM analysis detailed in Table 2, the magnesium bisglycinate group had a statistically significantly greater between-group mean reduction in ISI scores from baseline to Week 4 [−3.9 (95% CI, −5.8 to −2.0)] compared to the placebo group [−2.3 (95% CI, −4.1 to −0.4)] (p = 0.049).”
    Study
    RCT
    Duration
    4 weeks
    Interests
    An author is affiliated with a producer
    Dose studied
    magnesium bisglycinate, two capsules daily 30-60 minutes before bedtime, 250 mg elemental magnesium and 1523 mg glycine per day
    Population
    Adults aged 18 to 65 years in good health reporting poor sleep for more than four weeks (RIS score above 12); intention-to-treat, GLMM-adjusted for baseline ISI, age, sex, BMI and occupation

Study record

Design
randomised controlled trial
Species
human
Population
Healthy adults aged 18 to 65 reporting poor sleep quality
Participants
155
Comparator
placebo
Duration
28 days
Endpoints measured
27